Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2018 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.0%

Madrigal Pharmaceuticals reported a loss of $0.45 per share, which was in line with expectations, but no revenue figures were disclosed. The stock reacted negatively, dropping 1.0%, likely due to the absence of revenue data and guidance. Investors may be cautious as the company continues to navigate its clinical trials without clear financial direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.45	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on their clinical development despite the lack of specific guidance. They emphasized the significance of their ongoing trials.

Management expressed a commitment to advancing their clinical programs.

They noted the importance of upcoming trials in shaping future results.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.0%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.0%

Key numbers

Management commentary